ARCs	Antibody-radionuclide conjugates
ADCs	Antibody-drug conjugates
cORR	Confirmed objective response rate
Claudin 18.2	CLDN18.2
ATMis	Ataxia telangiectasia mutated inhibitors
BsAbs	Bispecific antibodies
DARPins	Designed ankyrin repeat proteins
ESPs	Engineered scaffold proteins
ICIs	Immune checkpoint inhibitors
IEDDA	Inverse-electron demand Diels–Alder
PNA	Peptide nucleic acid
SADA	Self-assembling and disassembling
scFv	Single-chain variable fragments
TCO	Trans-cyclooctene
Tz	Tetrazine
VHH	Variable domains of heavy-chain antibodies
PRIT	Pretargeted radioimmunotherapy
PARPis	Poly (adenosine diphosphate-ribose) polymerase inhibitors
ICD	Immunogenic cell death
DDRis	DNA damage response inhibitors
TCR	T cell receptor
Ti-Treg	Tumor-infiltrating regulatory T cells
TME	Tumor microenvironment
PSMA	Prostate-specific membrane antigen